A study conducted by Ergun Y et al. suggested that individuals with early breast cancer, regardless of hormone receptor status, experience longer disease-free survival (DFS) and overall survival (OS) if they had low HER2 expression instead of HER2-0 expression [35]. This evidence concerns the gene ERBB2 and breast carcinoma.